Trade Heron Therapeutics, Inc. - HRTX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Heron Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 1.2 |
Open* | 1.16 |
1-Year Change* | -56.72% |
Day's Range* | 1.16 - 1.31 |
52 wk Range | 0.50-3.41 |
Average Volume (10 days) | 7.15M |
Average Volume (3 months) | 57.90M |
Market Cap | 196.60M |
P/E Ratio | -100.00K |
Shares Outstanding | 150.07M |
Revenue | 122.84M |
EPS | -0.97 |
Dividend (Yield %) | N/A |
Beta | 1.53 |
Next Earnings Date | Mar 21, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 1, 2023 | 1.31 | 0.11 | 9.17% | 1.20 | 1.31 | 1.15 |
Nov 30, 2023 | 1.20 | -0.07 | -5.51% | 1.27 | 1.31 | 1.19 |
Nov 29, 2023 | 1.27 | 0.07 | 5.83% | 1.20 | 1.33 | 1.20 |
Nov 28, 2023 | 1.19 | 0.03 | 2.59% | 1.16 | 1.25 | 1.10 |
Nov 27, 2023 | 1.29 | -0.07 | -5.15% | 1.36 | 1.38 | 1.22 |
Nov 24, 2023 | 1.36 | 0.07 | 5.43% | 1.29 | 1.41 | 1.29 |
Nov 22, 2023 | 1.35 | 0.05 | 3.85% | 1.30 | 1.37 | 1.22 |
Nov 21, 2023 | 1.29 | -0.02 | -1.53% | 1.31 | 1.40 | 1.21 |
Nov 20, 2023 | 1.27 | 0.17 | 15.45% | 1.10 | 1.36 | 1.09 |
Nov 17, 2023 | 1.06 | 0.20 | 23.26% | 0.86 | 1.08 | 0.85 |
Nov 16, 2023 | 0.89 | 0.01 | 1.14% | 0.88 | 0.92 | 0.80 |
Nov 15, 2023 | 0.84 | 0.09 | 12.00% | 0.75 | 0.89 | 0.74 |
Nov 14, 2023 | 0.51 | -0.02 | -3.77% | 0.53 | 0.59 | 0.51 |
Nov 13, 2023 | 0.52 | -0.06 | -10.34% | 0.58 | 0.58 | 0.51 |
Nov 10, 2023 | 0.56 | -0.01 | -1.75% | 0.57 | 0.57 | 0.52 |
Nov 9, 2023 | 0.58 | -0.13 | -18.31% | 0.71 | 0.71 | 0.57 |
Nov 8, 2023 | 0.70 | -0.09 | -11.39% | 0.79 | 0.79 | 0.69 |
Nov 7, 2023 | 0.76 | 0.02 | 2.70% | 0.74 | 0.78 | 0.70 |
Nov 6, 2023 | 0.71 | -0.06 | -7.79% | 0.77 | 0.77 | 0.70 |
Nov 3, 2023 | 0.72 | 0.06 | 9.09% | 0.66 | 0.74 | 0.66 |
Heron Therapeutics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, March 21, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q4 2023 Heron Therapeutics Inc Earnings Release Q4 2023 Heron Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 107.672 | 86.346 | 88.638 | 145.968 | 77.474 |
Revenue | 107.672 | 86.346 | 88.638 | 145.968 | 77.474 |
Cost of Revenue, Total | 54.874 | 46.021 | 36.189 | 61.619 | 27.512 |
Gross Profit | 52.798 | 40.325 | 52.449 | 84.349 | 49.962 |
Total Operating Expense | 282.33 | 304.174 | 316.801 | 356.662 | 261.411 |
Selling/General/Admin. Expenses, Total | 119.95 | 127.332 | 106.079 | 127.661 | 93.867 |
Research & Development | 107.506 | 130.821 | 174.533 | 167.382 | 140.032 |
Operating Income | -174.658 | -217.828 | -228.163 | -210.694 | -183.937 |
Interest Income (Expense), Net Non-Operating | -0.836 | -1.977 | 1.732 | 5.787 | 3.293 |
Other, Net | -6.53 | -0.878 | -0.847 | 0.158 | 1.804 |
Net Income Before Taxes | -182.024 | -220.683 | -227.278 | -204.749 | -178.84 |
Net Income After Taxes | -182.024 | -220.683 | -227.278 | -204.749 | -178.84 |
Net Income Before Extra. Items | -182.024 | -220.683 | -227.278 | -204.749 | -178.84 |
Net Income | -182.024 | -220.683 | -227.278 | -204.749 | -178.84 |
Income Available to Common Excl. Extra. Items | -182.024 | -220.683 | -227.278 | -204.749 | -178.84 |
Income Available to Common Incl. Extra. Items | -182.024 | -220.683 | -227.278 | -204.749 | -178.84 |
Diluted Net Income | -182.024 | -220.683 | -227.278 | -204.749 | -178.84 |
Diluted Weighted Average Shares | 108.876 | 98.471 | 90.774 | 81.779 | 73.193 |
Diluted EPS Excluding Extraordinary Items | -1.67185 | -2.2411 | -2.50378 | -2.50369 | -2.4434 |
Diluted Normalized EPS | -1.67185 | -2.2411 | -2.50378 | -2.50369 | -2.4434 |
Total Extraordinary Items | 0 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 31.762 | 29.615 | 30.028 | 26.557 | 27.63 |
Revenue | 31.762 | 29.615 | 30.028 | 26.557 | 27.63 |
Cost of Revenue, Total | 20.158 | 16.854 | 12.627 | 14.717 | 16.175 |
Gross Profit | 11.604 | 12.761 | 17.401 | 11.84 | 11.455 |
Total Operating Expense | 74.165 | 62.678 | 50.383 | 68.439 | 77.128 |
Selling/General/Admin. Expenses, Total | 36.435 | 32.007 | 26.699 | 28.177 | 32.119 |
Research & Development | 17.572 | 13.817 | 11.057 | 25.545 | 28.834 |
Operating Income | -42.403 | -33.063 | -20.355 | -41.882 | -49.498 |
Other, Net | 0.344 | 0.295 | 0.486 | -0.026 | -6.861 |
Net Income Before Taxes | -42.059 | -32.768 | -19.869 | -41.908 | -56.359 |
Net Income After Taxes | -42.059 | -32.768 | -19.869 | -41.908 | -56.359 |
Net Income Before Extra. Items | -42.059 | -32.768 | -19.869 | -41.908 | -56.359 |
Net Income | -42.059 | -32.768 | -19.869 | -41.908 | -56.359 |
Income Available to Common Excl. Extra. Items | -42.059 | -32.768 | -19.869 | -41.908 | -56.359 |
Income Available to Common Incl. Extra. Items | -42.059 | -32.768 | -19.869 | -41.908 | -56.359 |
Diluted Net Income | -42.059 | -32.768 | -19.869 | -41.908 | -56.359 |
Diluted Weighted Average Shares | 119.719 | 119.246 | 119.136 | 111.735 | 102.405 |
Diluted EPS Excluding Extraordinary Items | -0.35131 | -0.27479 | -0.16678 | -0.37507 | -0.55035 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.35131 | -0.27479 | -0.16678 | -0.37507 | -0.55035 |
Interest Income (Expense), Net Non-Operating |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 205.435 | 254.423 | 314.196 | 479.064 | 447.248 |
Cash and Short Term Investments | 84.852 | 157.58 | 208.491 | 390.972 | 332.371 |
Cash & Equivalents | 15.364 | 90.541 | 105.138 | 71.898 | 31.836 |
Short Term Investments | 69.488 | 67.039 | 103.353 | 319.074 | 300.535 |
Total Receivables, Net | 52.049 | 35.499 | 41.85 | 39.879 | 64.652 |
Accounts Receivable - Trade, Net | 52.049 | 35.499 | 41.85 | 39.879 | 64.652 |
Total Inventory | 54.573 | 48.382 | 41.905 | 24.968 | 39.032 |
Prepaid Expenses | 13.961 | 12.962 | 21.95 | 23.245 | 11.193 |
Total Assets | 250.951 | 305.706 | 353.556 | 512.782 | 462.179 |
Property/Plant/Equipment, Total - Net | 29.805 | 33.563 | 39.014 | 33.372 | 14.677 |
Property/Plant/Equipment, Total - Gross | 44.098 | 46.806 | 49.886 | 41.397 | 22.772 |
Accumulated Depreciation, Total | -14.293 | -13.243 | -10.872 | -8.025 | -8.095 |
Other Long Term Assets, Total | 15.711 | 17.72 | 0.346 | 0.346 | 0.254 |
Total Current Liabilities | 82.355 | 71.058 | 102.503 | 96.705 | 92.019 |
Accounts Payable | 3.225 | 3.803 | 0.525 | 2.758 | 16.863 |
Accrued Expenses | 78.131 | 66.622 | 94.577 | 88.323 | 70.582 |
Notes Payable/Short Term Debt | 0 | 0 | 7.053 | 5.624 | 4.574 |
Current Port. of LT Debt/Capital Leases | 0 | ||||
Other Current Liabilities, Total | 0.999 | 0.633 | 0.348 | 0 | |
Total Liabilities | 237.379 | 228.136 | 117.064 | 108.947 | 92.019 |
Total Long Term Debt | 149.284 | 149.082 | 0 | 0 | 0 |
Long Term Debt | 149.284 | 149.082 | |||
Total Equity | 13.572 | 77.57 | 236.492 | 403.835 | 370.16 |
Preferred Stock - Non Redeemable, Net | 0 | ||||
Common Stock | 1.191 | 1.02 | 0.913 | 0.903 | 0.782 |
Additional Paid-In Capital | 1807.85 | 1689.99 | 1628.07 | 1568.32 | 1330.19 |
Retained Earnings (Accumulated Deficit) | -1795.45 | -1613.43 | -1392.75 | -1165.47 | -960.721 |
Other Equity, Total | -0.019 | -0.006 | 0.257 | 0.085 | -0.087 |
Total Liabilities & Shareholders’ Equity | 250.951 | 305.706 | 353.556 | 512.782 | 462.179 |
Total Common Shares Outstanding | 119.155 | 102.005 | 91.31 | 90.304 | 78.174 |
Other Liabilities, Total | 5.74 | 7.996 | 14.561 | 12.242 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 193.979 | 165.28 | 178.159 | 205.435 | 223.804 |
Cash and Short Term Investments | 77.412 | 33.244 | 60.022 | 84.852 | 121.746 |
Cash & Equivalents | 34.859 | 13.462 | 27.09 | 15.364 | 50.438 |
Short Term Investments | 42.553 | 19.782 | 32.932 | 69.488 | 71.308 |
Total Receivables, Net | 63.795 | 76.693 | 51.448 | 52.049 | 42.188 |
Accounts Receivable - Trade, Net | 63.795 | 76.693 | 51.448 | 52.049 | 42.188 |
Total Inventory | 42.007 | 44.623 | 52.059 | 54.573 | 52.239 |
Prepaid Expenses | 10.765 | 10.72 | 14.63 | 13.961 | 7.631 |
Total Assets | 229.199 | 201.224 | 220.878 | 250.951 | 271.952 |
Property/Plant/Equipment, Total - Net | 26.854 | 27.361 | 28.583 | 29.805 | 30.823 |
Other Long Term Assets, Total | 8.366 | 8.583 | 14.136 | 15.711 | 17.325 |
Total Current Liabilities | 79.745 | 86.722 | 77.9 | 82.355 | 93.876 |
Accounts Payable | 1.86 | 1.957 | 4.065 | 3.225 | 6.547 |
Accrued Expenses | 77.885 | 84.765 | 73.835 | 79.13 | 87.329 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 256.985 | 240.508 | 232.307 | 237.379 | 249.502 |
Total Long Term Debt | 149.439 | 149.387 | 149.335 | 149.284 | 149.234 |
Other Liabilities, Total | 27.801 | 4.399 | 5.072 | 5.74 | 6.392 |
Total Equity | -27.786 | -39.284 | -11.429 | 13.572 | 22.45 |
Common Stock | 1.411 | 1.199 | 1.193 | 1.191 | 1.188 |
Additional Paid-In Capital | 1866.09 | 1829.81 | 1815.59 | 1807.85 | 1796.91 |
Retained Earnings (Accumulated Deficit) | -1895.29 | -1870.28 | -1828.22 | -1795.45 | -1775.59 |
Other Equity, Total | -0.001 | -0.006 | 0.009 | -0.019 | -0.057 |
Total Liabilities & Shareholders’ Equity | 229.199 | 201.224 | 220.878 | 250.951 | 271.952 |
Total Common Shares Outstanding | 141.101 | 119.956 | 119.28 | 119.155 | 118.774 |
Long Term Debt | 149.439 | 149.387 | 149.335 | 149.284 | 149.234 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -182.024 | -220.683 | -227.278 | -204.749 | -178.84 |
Cash From Operating Activities | -146.912 | -203.354 | -184.82 | -124.58 | -191.805 |
Cash From Operating Activities | 2.889 | 3.021 | 2.847 | 2.044 | 1.513 |
Non-Cash Items | 42.729 | 49.387 | 52.619 | 48.892 | 30.946 |
Cash Interest Paid | 2.25 | 1.244 | 0 | 0 | 1.183 |
Changes in Working Capital | -10.506 | -35.079 | -13.008 | 29.233 | -45.424 |
Cash From Investing Activities | -3.324 | 32.729 | 208.955 | -21.783 | -278.55 |
Capital Expenditures | -1.825 | -3.022 | -6.813 | -7.154 | -9.171 |
Other Investing Cash Flow Items, Total | -1.499 | 35.751 | 215.768 | -14.629 | -269.379 |
Cash From Financing Activities | 75.059 | 156.028 | 9.105 | 186.425 | 357.608 |
Issuance (Retirement) of Stock, Net | 75.059 | 7.065 | 9.079 | 186.425 | 382.608 |
Issuance (Retirement) of Debt, Net | 0 | 148.963 | -25 | ||
Net Change in Cash | -75.177 | -14.597 | 33.24 | 40.062 | -112.747 |
Financing Cash Flow Items | 0.026 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -32.768 | -182.024 | -162.155 | -120.247 | -63.888 |
Cash From Operating Activities | -24.9 | -146.912 | -109.378 | -72.312 | -43.939 |
Cash From Operating Activities | 0.718 | 2.889 | 2.098 | 1.392 | 0.721 |
Non-Cash Items | 7.678 | 42.729 | 32.66 | 21.645 | 11.212 |
Changes in Working Capital | -0.528 | -10.506 | 18.019 | 24.898 | 8.016 |
Cash From Investing Activities | 36.834 | -3.324 | -5.345 | 30.702 | 10.946 |
Capital Expenditures | -0.224 | -1.825 | -1.411 | -1.366 | -1.044 |
Other Investing Cash Flow Items, Total | 37.058 | -1.499 | -3.934 | 32.068 | 11.99 |
Cash From Financing Activities | -0.208 | 75.059 | 74.62 | -0.322 | -0.637 |
Issuance (Retirement) of Stock, Net | -0.208 | 75.059 | 74.62 | -0.322 | -0.637 |
Net Change in Cash | 11.726 | -75.177 | -40.103 | -41.932 | -33.63 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | ||
Cash Interest Paid | 0 | 2.25 | 1.125 | 1.125 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Rubric Capital Management LP | Hedge Fund | 18.9781 | 26713503 | 14963503 | 2023-07-25 | MED |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.7834 | 8140722 | -273644 | 2023-06-30 | LOW |
Baker Bros. Advisors LP | Hedge Fund | 5.777 | 8131678 | 0 | 2023-06-30 | LOW |
Franklin Advisers, Inc. | Investment Advisor/Hedge Fund | 5.2649 | 7410822 | -4373808 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.9654 | 6989211 | -112839 | 2023-06-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 4.1989 | 5910312 | -220901 | 2023-06-30 | LOW |
Great Point Partners, LLC | Hedge Fund | 3.3656 | 4737368 | -1080000 | 2023-06-30 | HIGH |
Velan Capital Investment Management LP | Investment Advisor/Hedge Fund | 3.1969 | 4500000 | 0 | 2023-06-30 | HIGH |
Palisade Capital Management, LLC | Investment Advisor/Hedge Fund | 2.9438 | 4143649 | 173363 | 2023-06-30 | LOW |
Clearline Capital LP | Hedge Fund | 1.894 | 2665984 | 576692 | 2023-06-30 | HIGH |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.6562 | 2331238 | -224755 | 2023-06-30 | LOW |
JW Asset Management, LLC | Hedge Fund | 1.5682 | 2207418 | 2207418 | 2023-06-30 | LOW |
Deep Track Capital LP | Hedge Fund | 1.4825 | 2086704 | -1148018 | 2023-06-30 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.4595 | 2054426 | 79472 | 2023-06-30 | LOW |
Tang Capital Management, LLC | Hedge Fund | 1.3148 | 1850760 | 1300000 | 2023-06-30 | MED |
Tejara Capital Ltd. | Investment Advisor | 1.1652 | 1640133 | -27386 | 2023-06-30 | HIGH |
Orchard Capital Management LLC | Investment Advisor | 0.9883 | 1391080 | 0 | 2023-06-30 | MED |
Jefferies LLC | Research Firm | 0.9171 | 1290924 | 1290924 | 2023-06-30 | HIGH |
Coho Partners, Ltd. | Investment Advisor | 0.8888 | 1251123 | 0 | 2023-04-30 | LOW |
New York State Common Retirement Fund | Pension Fund | 0.7892 | 1110876 | 39752 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Heron Therapeutics, Inc. Company profile
About Heron Therapeutics Inc
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF (HTX-011), HTX-019, and HTX-034. HTX-011 is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting. HTX-034 is a product candidate for postoperative pain management.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Heron Therapeutics Inc revenues decreased 3% to $86.3M. Net loss decreased 3% to $220.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects "Research and development - Balancing va decrease of 39% to $66.4M (expense), Stock-based Compensation in SGA decrease of 24% to $11.8M (expense).
Equity composition
Common Stock $.01 Par, 02/10, 50M auth., 40,143,227 issd. Insiders own 6.70%. IPO: 8/87, 2M shares @ $7.00 by Allen & Co. 2/92, private placement of 1,150,000 units (1 Share + 1 Warrant). 5/01, Name changed from Advanced Polymer Systems, Inc. FY'01 fncls. are restated. 05/07, 1-for-4 reverse stock split. 01/14, 1-for-20 Reverse stock split.
Industry: | Biotechnology & Medical Research (NEC) |
4242 Campus Point Court, Suite 200
SAN DIEGO
CALIFORNIA 92121
US
Income Statement
- Annual
- Quarterly
News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com